Rosetta Genomics Ltd (ROSG) 0.90 $ROSG Rosetta
Post# of 273254
Posted On: 09/22/2016 3:20:25 PM
Rosetta Genomics Ltd (ROSG) 0.90 $ROSG
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016
BusinessWire - Tue Sep 20, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended June 30, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC"
after the closing of the U.S. financial markets on September 26, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com.
ROSG: 0.90 (-0.02)
Rosetta Genomics to Present at Upcoming September Conferences
BusinessWire - Mon Sep 19, 8:00AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be delivering a corporate overview at the 2016 Aegis Growth Conference taking place September 20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016 Healthcare Conference taking place on September 27, 2016 in New York City.
ROSG: 0.90 (-0.02)
Data Validating the Utility of RosettaGX Reveal(TM) with Liquid-based Cytology Samples will be Presented at the 86th Annual Meeting of the American Thyroid Association
BusinessWire - Wed Sep 14, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company's first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal(TM) ("Reveal" , can now be used with liquid-based cytology samples (ThinPrep(R)). The data will be presented in a poster at the upcoming 86th Annual Meeting of the American Thyroid Association taking place from September 21-25, 2016 at the Sheraton Denver Downtown Hotel in Denver, Colorado.
ROSG: 0.90 (-0.02)
RosettaGX Reveal(TM) Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep(R) Samples
BusinessWire - Wed Sep 07, 7:30AM CDT
--Updates on Commercial Progress with Reveal
ROSG: 0.90 (-0.02)
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer
BusinessWire - Wed Aug 24, 8:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global pharmaceutical company to provide Fluorescence in Situ Hybridization (FISH) testing services for a clinical study the pharmaceutical company is conducting in prostate cancer.
ROSG: 0.90 (-0.02)
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect(TM) from Admera Health
BusinessWire - Thu Aug 04, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect(TM), a next generation sequencing (NGS)-based test that detects somatic mutations frequently found in cancers and provides actionable results to help guide therapeutic decisions related to targeted cancer therapies.
ROSG: 0.90 (-0.02)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Tue Aug 02, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Galaxy Health Network, as a preferred laboratory provider.
ROSG: 0.90 (-0.02)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
BusinessWire - Thu Jun 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc., as a preferred laboratory provider.
ROSG: 0.90 (-0.02)
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay
BusinessWire - Thu May 26, 6:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology. The article, "Analytical Validity of a microRNA-based Assay for Diagnosing Indeterminate Thyroid FNA Smears from Routinely Prepared Cytology Slides," highlights the robustness of RosettaGX Reveal(TM), a test that stratifies indeterminate thyroid lesions as "benign," "suspicious for malignancy by microRNA" or "positive for medullary carcinoma" in preoperative Fine Needle Aspirate (FNA) by utilizing existing cytology smear samples. The article can be accessed here.
ROSG: 0.90 (-0.02)
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays
BusinessWire - Mon May 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the Company's allele-specific PCR (CAST PCR)-based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers. NYSDOH approval was granted under the Company's Molecular Oncology and Cellular Tumor Marker permit.
ROSG: 0.90 (-0.02)
Rosetta Genomics Reports 2016 First Quarter Financial Results
BusinessWire - Thu May 19, 7:00AM CDT
--Conference call begins today at 10:00 a.m. Eastern time
ROSG: 0.90 (-0.02)
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016
BusinessWire - Mon May 16, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC" before the opening of the U.S. financial markets on May, 19, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com.
ROSG: 0.90 (-0.02)
Rosetta Genomics Announces Agreement with America's Choice Provider Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Mon Feb 01, 7:00AM CST
--Includes RosettaGX Reveal(TM) for classification of indeterminate thyroid nodules, increasing the covered lives for this first-of-its kind assay to over 150 million
ROSG: 0.90 (-0.02)
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors
BusinessWire - Mon Jan 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to "Gene Expression Signature for Classification of Kidney Tumors." The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).
ROSG: 0.90 (-0.02)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 0.90 (-0.02), RGLS: 3.42 (+0.01)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 0.90 (-0.02), RGLS: 3.42 (+0.01)
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics
BusinessWire - Wed Jan 06, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta's patents related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna's MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.
ROSG: 0.90 (-0.02), MIRN: 1.96 (-0.04)
BUYINS.NET: PTH, GOODO, ROSG, FXH, USL, MGC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Dec 22, 6:42AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Dynamic Heathcare Sector Portfolio (NYSE
TH), Gladstone Commercial Corp (NASDAQ:GOODO), Rosetta Genomics Ltd (NASDAQ:ROSG), First Trust Health Care AlphaDEX Fund (NYSE:FXH), United States 12 Month Oil Fund LP (NYSE:USL), Midasco Capital Corp (NYSE:MGC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ROSG: 0.90 (-0.02), MGC: 74.14 (+0.48), PTH: 54.22 (+0.69), GOOD: 18.84 (+0.44), FXH: 61.47 (+0.60), GOODO: 25.34 (-0.01), USL: 18.11 (+0.27)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 0.90 (-0.02), BIOD: 0.43 (+0.01)
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis
BusinessWire - Mon Dec 14, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc. (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announce the successful completion of feasibility studies under a previously announced collaboration to evaluate the use of Biocept's patented microfluidic channel technology to extract circulating tumor cells (CTCs) from blood and Rosetta Genomics' technical expertise and proprietary qRT-PCR platform to characterize microRNAs isolated from those CTCs.
ROSG: 0.90 (-0.02), BIOC: 0.59 (unch)
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016
BusinessWire - Tue Sep 20, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended June 30, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC"
after the closing of the U.S. financial markets on September 26, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com. ROSG: 0.90 (-0.02)
Rosetta Genomics to Present at Upcoming September Conferences
BusinessWire - Mon Sep 19, 8:00AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be delivering a corporate overview at the 2016 Aegis Growth Conference taking place September 20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016 Healthcare Conference taking place on September 27, 2016 in New York City.
ROSG: 0.90 (-0.02)
Data Validating the Utility of RosettaGX Reveal(TM) with Liquid-based Cytology Samples will be Presented at the 86th Annual Meeting of the American Thyroid Association
BusinessWire - Wed Sep 14, 8:09AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company's first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal(TM) ("Reveal"
, can now be used with liquid-based cytology samples (ThinPrep(R)). The data will be presented in a poster at the upcoming 86th Annual Meeting of the American Thyroid Association taking place from September 21-25, 2016 at the Sheraton Denver Downtown Hotel in Denver, Colorado. ROSG: 0.90 (-0.02)
RosettaGX Reveal(TM) Thyroid miRNA Classifier Now Available to Be Utilized on ThinPrep(R) Samples
BusinessWire - Wed Sep 07, 7:30AM CDT
--Updates on Commercial Progress with Reveal
ROSG: 0.90 (-0.02)
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer
BusinessWire - Wed Aug 24, 8:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the Company has entered into a services agreement with an unnamed global pharmaceutical company to provide Fluorescence in Situ Hybridization (FISH) testing services for a clinical study the pharmaceutical company is conducting in prostate cancer.
ROSG: 0.90 (-0.02)
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect(TM) from Admera Health
BusinessWire - Thu Aug 04, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of OncoGxSelect(TM), a next generation sequencing (NGS)-based test that detects somatic mutations frequently found in cancers and provides actionable results to help guide therapeutic decisions related to targeted cancer therapies.
ROSG: 0.90 (-0.02)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement with Galaxy Health Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Tue Aug 02, 7:15AM CDT
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Galaxy Health Network, as a preferred laboratory provider.
ROSG: 0.90 (-0.02)
Rosetta Expands Managed Care Coverage with New Preferred Provider Agreement for Entire Suite of Diagnostic Tests and Services
BusinessWire - Thu Jun 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc., as a preferred laboratory provider.
ROSG: 0.90 (-0.02)
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay
BusinessWire - Thu May 26, 6:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for the classification of indeterminate thyroid nodules have been published online in the peer-reviewed journal, Cancer Cytopathology. The article, "Analytical Validity of a microRNA-based Assay for Diagnosing Indeterminate Thyroid FNA Smears from Routinely Prepared Cytology Slides," highlights the robustness of RosettaGX Reveal(TM), a test that stratifies indeterminate thyroid lesions as "benign," "suspicious for malignancy by microRNA" or "positive for medullary carcinoma" in preoperative Fine Needle Aspirate (FNA) by utilizing existing cytology smear samples. The article can be accessed here.
ROSG: 0.90 (-0.02)
Rosetta Genomics Receives Approval from New York State for Four PCR-Based Assays
BusinessWire - Mon May 23, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health (NYSDOH) for the Company's allele-specific PCR (CAST PCR)-based assays to test for BRAF, EGFR, KRAS and NRAS mutations in lung, colon and melanoma cancers. NYSDOH approval was granted under the Company's Molecular Oncology and Cellular Tumor Marker permit.
ROSG: 0.90 (-0.02)
Rosetta Genomics Reports 2016 First Quarter Financial Results
BusinessWire - Thu May 19, 7:00AM CDT
--Conference call begins today at 10:00 a.m. Eastern time
ROSG: 0.90 (-0.02)
Rosetta Genomics to Host 2016 First Quarter Financial Results and Business Update Conference Call on May 19, 2016
BusinessWire - Mon May 16, 7:00AM CDT
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC"
before the opening of the U.S. financial markets on May, 19, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com. ROSG: 0.90 (-0.02)
Rosetta Genomics Announces Agreement with America's Choice Provider Network for Entire Suite of Diagnostic Tests and Services
BusinessWire - Mon Feb 01, 7:00AM CST
--Includes RosettaGX Reveal(TM) for classification of indeterminate thyroid nodules, increasing the covered lives for this first-of-its kind assay to over 150 million
ROSG: 0.90 (-0.02)
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors
BusinessWire - Mon Jan 25, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to "Gene Expression Signature for Classification of Kidney Tumors." The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).
ROSG: 0.90 (-0.02)
CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 9:19AM CST
Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer). In addition, there is a change to the first paragraph, first sentence. "U.S. Patent" should read "European Patent."
ROSG: 0.90 (-0.02), RGLS: 3.42 (+0.01)
Rosetta Genomics Granted U.S. Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer
BusinessWire - Mon Jan 11, 8:11AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the U.S. Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 08844596.0, relating to "Targeting microRNAs for the Treatment of Liver Cancer." This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq:RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.
ROSG: 0.90 (-0.02), RGLS: 3.42 (+0.01)
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics
BusinessWire - Wed Jan 06, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta's patents related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna's MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.
ROSG: 0.90 (-0.02), MIRN: 1.96 (-0.04)
BUYINS.NET: PTH, GOODO, ROSG, FXH, USL, MGC Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Dec 22, 6:42AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Dynamic Heathcare Sector Portfolio (NYSE
TH), Gladstone Commercial Corp (NASDAQ:GOODO), Rosetta Genomics Ltd (NASDAQ:ROSG), First Trust Health Care AlphaDEX Fund (NYSE:FXH), United States 12 Month Oil Fund LP (NYSE:USL), Midasco Capital Corp (NYSE:MGC) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: ROSG: 0.90 (-0.02), MGC: 74.14 (+0.48), PTH: 54.22 (+0.69), GOOD: 18.84 (+0.44), FXH: 61.47 (+0.60), GOODO: 25.34 (-0.01), USL: 18.11 (+0.27)
4 Stocks Under $10 Showing Great Upside Today
ACCESSWIRE - Fri Dec 18, 9:47AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
FREE: 1.15 (-0.52), OCAT: 8.47 (+0.01), ROSG: 0.90 (-0.02), BIOD: 0.43 (+0.01)
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis
BusinessWire - Mon Dec 14, 7:00AM CST
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc. (NASDAQ:BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announce the successful completion of feasibility studies under a previously announced collaboration to evaluate the use of Biocept's patented microfluidic channel technology to extract circulating tumor cells (CTCs) from blood and Rosetta Genomics' technical expertise and proprietary qRT-PCR platform to characterize microRNAs isolated from those CTCs.
ROSG: 0.90 (-0.02), BIOC: 0.59 (unch)
(0)
(0)Scroll down for more posts ▼